Cellectis S.A. (CMVLF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cellectis S.A. (CMVLF) with AI Score 51/100 (Hold). Cellectis S. A. is a clinical-stage biotechnology company focused on developing allogeneic T-cell therapies for cancer. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Cellectis S.A. (CMVLF) Healthcare & Pipeline Overview
Cellectis S.A. is a clinical-stage biotechnology firm specializing in gene-edited allogeneic CAR-T cell therapies for cancer treatment. With a focus on hematologic malignancies and solid tumors, Cellectis is developing off-the-shelf immunotherapies, holding strategic alliances to advance its pipeline and address unmet medical needs in oncology.
Investment Thesis
Cellectis S.A. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's allogeneic CAR-T cell therapy platform offers the potential to overcome limitations associated with autologous CAR-T therapies, such as manufacturing complexities and patient-specific variability. Key value drivers include the clinical progress of its lead product candidates, particularly UCART19, ALLO-501, and ALLO-501A, with clinical trial results serving as significant catalysts. The strategic alliances with Allogene, Servier, and other partners provide financial support and validation of Cellectis' technology. However, the company faces significant challenges, including clinical trial risks, regulatory hurdles, and competition from other CAR-T therapy developers. With a negative P/E ratio of -10.23 and a negative profit margin of -47.0%, the company's financial performance relies heavily on future clinical and commercial success. The high beta of 2.85 indicates significant volatility.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.33 billion reflects investor sentiment regarding Cellectis' potential in the CAR-T therapy space.
- Gross margin of 91.0% indicates strong potential profitability for successful products.
- Strategic alliances with Allogene Therapeutics and Les Laboratoires Servier provide financial support and development expertise.
- Focus on allogeneic CAR-T therapies addresses limitations of autologous therapies, potentially offering scalability and cost advantages.
- Pipeline includes multiple clinical-stage assets targeting various hematologic malignancies and solid tumors, diversifying risk.
Competitors & Peers
Strengths
- Proprietary gene-editing technology
- Allogeneic CAR-T cell platform
- Strategic alliances with major pharmaceutical companies
- Experienced management team
Weaknesses
- Clinical-stage company with no approved products
- High R&D costs
- Dependence on strategic alliances for funding
- Negative profit margin
Catalysts
- Upcoming: Clinical trial results for UCART19 in acute lymphoblastic leukemia.
- Upcoming: Clinical trial results for ALLO-501 and ALLO-501A in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma.
- Upcoming: Regulatory submissions for potential product approvals.
- Ongoing: Advancement of gene-editing technology to improve CAR-T cell therapies.
- Ongoing: Expansion of strategic alliances and collaborations.
Risks
- Potential: Clinical trial failures and regulatory setbacks.
- Potential: Competition from other CAR-T therapy developers.
- Potential: Patent disputes and intellectual property challenges.
- Ongoing: High R&D costs and dependence on strategic alliances for funding.
- Ongoing: Limited liquidity and price volatility on the OTC market.
Growth Opportunities
- Expansion of Clinical Trials: Cellectis has the opportunity to expand its clinical trials to include a broader range of hematologic malignancies and solid tumors. This expansion would allow the company to gather more data on the safety and efficacy of its allogeneic CAR-T therapies, potentially leading to regulatory approvals and commercialization. The global oncology market is projected to reach $350 billion by 2030, providing a substantial market opportunity for Cellectis' therapies. Timeline: Ongoing, with continuous enrollment and initiation of new trials.
- Strategic Partnerships and Collaborations: Cellectis can leverage strategic partnerships and collaborations to accelerate the development and commercialization of its allogeneic CAR-T therapies. Collaborations with pharmaceutical companies, academic institutions, and other biotechnology companies can provide access to funding, expertise, and resources. The market for strategic alliances in the biotechnology industry is estimated at $100 billion annually. Timeline: Ongoing, with potential for new partnerships in the next 1-3 years.
- Advancement of Gene-Editing Technology: Cellectis can further advance its gene-editing technology to improve the efficacy and safety of its allogeneic CAR-T therapies. This includes developing more precise and efficient gene-editing tools, as well as optimizing the design of CAR constructs. The global gene-editing market is projected to reach $10 billion by 2027. Timeline: Ongoing, with continuous research and development efforts.
- Geographic Expansion: Cellectis has the opportunity to expand its geographic presence beyond Europe and the United States. This expansion would allow the company to access new markets and patient populations, increasing the potential for commercial success. The emerging markets in Asia and Latin America offer significant growth opportunities for cancer therapies. Timeline: Potential expansion within the next 3-5 years.
- Development of Next-Generation CAR-T Therapies: Cellectis can focus on developing next-generation CAR-T therapies that address the limitations of current therapies, such as cytokine release syndrome (CRS) and neurotoxicity. This includes developing CAR-T therapies with improved safety profiles and enhanced efficacy. The market for next-generation CAR-T therapies is projected to grow rapidly as these therapies become more widely adopted. Timeline: Ongoing research and development, with potential for clinical trials in the next 2-4 years.
Opportunities
- Expansion of clinical trials to new indications
- Development of next-generation CAR-T therapies
- Geographic expansion to emerging markets
- Potential for regulatory approvals and commercialization
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other CAR-T therapy developers
- Patent disputes
Competitive Advantages
- Proprietary gene-editing technology for CAR-T cell development.
- Strategic alliances with leading pharmaceutical companies.
- Clinical-stage pipeline of allogeneic CAR-T therapies.
- Expertise in allogeneic CAR-T cell manufacturing.
About CMVLF
Founded in 1999 and headquartered in Paris, France, Cellectis S.A. is a clinical-stage biotechnology company pioneering the development of allogeneic, off-the-shelf T-cell therapies for cancer. The company's core technology revolves around gene editing, enabling the creation of chimeric antigen receptor (CAR) T-cells that can target and eradicate cancer cells. Cellectis operates through two segments: Therapeutics and Plants, with the primary focus on the Therapeutics segment. Its lead product candidates include UCART19, targeting CD19-expressing hematologic malignancies like acute lymphoblastic leukemia (ALL); ALLO-501 and ALLO-501A for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL); ALLO-316 for Renal Cell Carcinoma (RCC); UCART123 for acute myeloid leukemia (AML); UCART22 for B-cell ALL; and UCARTCS1 and ALLO-715 for multiple myeloma. Cellectis has established strategic alliances with companies like Allogene Therapeutics, Inc., Les Laboratoires Servier, Iovance Biotherapeutics, and Cytovia Therapeutics, as well as academic collaborations with institutions such as The University of Texas M.D. Anderson Cancer Center, to advance its research and development efforts. These collaborations are crucial for expanding the company's pipeline and accelerating the development of novel cancer immunotherapies.
What They Do
- Develops allogeneic CAR-T cell therapies for cancer treatment.
- Utilizes gene-editing technology to create off-the-shelf immunotherapies.
- Targets hematologic malignancies and solid tumors.
- Conducts clinical trials to evaluate the safety and efficacy of its therapies.
- Collaborates with pharmaceutical companies and academic institutions.
- Focuses on improving the safety and efficacy of CAR-T cell therapies.
- Operates through two segments: Therapeutics and Plants.
Business Model
- Develops and out-licenses CAR-T cell therapies.
- Generates revenue through strategic alliances and collaborations.
- Secures funding through venture capital and public offerings.
- Focuses on research and development to advance its pipeline.
Industry Context
Cellectis S.A. operates within the rapidly evolving biotechnology industry, specifically in the field of cancer immunotherapy. The CAR-T cell therapy market is projected to experience substantial growth, driven by the increasing prevalence of cancer and the limitations of traditional treatment options. Cellectis' focus on allogeneic CAR-T therapies positions it to compete with companies developing autologous CAR-T therapies, such as Novartis and Gilead Sciences, as well as other allogeneic CAR-T developers. The competitive landscape includes companies like CLVLF, CYDY, FGHQF, HLOSF, and HNSBF, each pursuing different approaches to cancer immunotherapy. The industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition.
Key Customers
- Patients with hematologic malignancies and solid tumors.
- Hospitals and cancer centers.
- Pharmaceutical companies through strategic alliances.
- Research institutions through collaborations.
Financials
Chart & Info
Cellectis S.A. (CMVLF) stock price: Price data unavailable
Latest News
-
Monthly information on share capital and company voting rights
GlobeNewswire · Feb 4, 2026
-
Stocks That Hit 52-Week Lows On Thursday
· Oct 10, 2019
-
Stocks That Hit 52-Week Lows On Tuesday
· Oct 8, 2019
-
Stocks That Hit 52-Week Lows On Friday
· Oct 4, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CMVLF.
Price Targets
Wall Street price target analysis for CMVLF.
MoonshotScore
What does this score mean?
The MoonshotScore rates CMVLF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Andre Choulika
CEO
Andre Choulika is the CEO of Cellectis S.A. He founded Cellectis in 1999. He holds a Ph.D. in Molecular Virology from the Institut Pasteur and an MBA from Collège des Ingénieurs. Prior to Cellectis, he worked as a researcher at the Institut Pasteur and served as a consultant for various biotechnology companies. His expertise lies in gene editing and immunotherapy.
Track Record: Under Andre Choulika's leadership, Cellectis has advanced its allogeneic CAR-T cell therapy platform and established strategic alliances with major pharmaceutical companies. He has overseen the development of Cellectis' pipeline of clinical-stage assets, including UCART19 and ALLO-501. He has also guided the company through multiple financing rounds and public offerings.
CMVLF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Cellectis S.A. (CMVLF) may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, may be thinly traded, and are subject to less stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks involves higher risk due to the potential for limited information, price volatility, and illiquidity. These stocks are often referred to as 'penny stocks'.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity and price volatility
- Lack of regulatory oversight and financial transparency
- Potential for fraud or manipulation
- Limited operating history and financial resources
- Higher risk of delisting or going out of business
- Verify the company's management team and their track record.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Understand the company's capital structure and funding sources.
- Monitor the company's trading volume and price activity.
- Consult with a qualified financial advisor.
- Strategic alliances with reputable pharmaceutical companies.
- Clinical-stage pipeline of CAR-T therapies.
- Experienced management team with expertise in gene editing and immunotherapy.
- Presence on the OTC market, indicating some level of public disclosure.
- Focus on developing innovative cancer therapies.
Common Questions About CMVLF
What does Cellectis S.A. do?
Cellectis S.A. is a clinical-stage biotechnology company focused on developing allogeneic CAR-T cell therapies for cancer. Unlike autologous CAR-T therapies, which are patient-specific, Cellectis' allogeneic therapies are designed to be off-the-shelf, meaning they can be manufactured in advance and readily available for use in multiple patients. This approach has the potential to overcome limitations associated with autologous therapies, such as manufacturing complexities, high costs, and patient-specific variability. The company's pipeline includes multiple clinical-stage assets targeting various hematologic malignancies and solid tumors.
What do analysts say about CMVLF stock?
Analyst coverage of CMVLF is limited due to its OTC listing and clinical-stage nature. However, analysts generally view Cellectis' allogeneic CAR-T cell therapy platform as promising, given its potential to address the limitations of autologous therapies. Key valuation metrics include the potential market size for its lead product candidates, the probability of clinical trial success, and the terms of its strategic alliances. Growth considerations include the company's ability to secure regulatory approvals, expand its pipeline, and maintain its competitive advantage in the CAR-T therapy space. It is important to note that investing in clinical-stage biotechnology companies involves significant risk.
What are the main risks for CMVLF?
The main risks for Cellectis S.A. include clinical trial failures, regulatory hurdles, and competition from other CAR-T therapy developers. Clinical trial failures can result in significant setbacks and delays, as well as a loss of investor confidence. Regulatory hurdles, such as the need to demonstrate safety and efficacy in clinical trials, can also delay or prevent the approval of its therapies. Competition from other CAR-T therapy developers, including those with more advanced clinical programs or greater financial resources, can limit Cellectis' market share and profitability. Additionally, the company faces risks associated with its dependence on strategic alliances for funding and its limited liquidity on the OTC market.
How does Cellectis S.A. navigate regulatory approval processes?
Cellectis S.A. navigates regulatory approval processes by adhering to stringent guidelines set by regulatory agencies like the FDA in the United States and the EMA in Europe. The company's strategy involves comprehensive preclinical studies to establish safety and efficacy, followed by well-designed clinical trials to demonstrate the therapeutic benefits of its CAR-T cell therapies. Cellectis maintains ongoing communication with regulatory bodies, ensuring compliance with evolving standards and addressing any concerns promptly. A strong emphasis is placed on data integrity, patient safety, and ethical conduct throughout the development and approval process. The company's track record includes successful IND (Investigational New Drug) applications and ongoing clinical trials, reflecting its commitment to regulatory compliance.
What are the key growth opportunities for CMVLF in healthcare?
Cellectis S.A. has several key growth opportunities within the healthcare sector. One significant avenue is the expansion into new therapeutic areas beyond hematologic malignancies, such as solid tumors, where the unmet medical need remains substantial. Geographic expansion into emerging markets, particularly in Asia, presents another growth opportunity, as these regions often have a high prevalence of cancer and increasing access to innovative therapies. Furthermore, Cellectis can leverage its gene-editing technology to develop next-generation CAR-T therapies with improved safety profiles and enhanced efficacy, potentially capturing a larger share of the CAR-T therapy market. Strategic partnerships with pharmaceutical companies and academic institutions can also accelerate the development and commercialization of its therapies, driving future growth.
What are the key factors to evaluate for CMVLF?
Cellectis S.A. (CMVLF) currently holds an AI score of 51/100, indicating moderate score. Key strength: Proprietary gene-editing technology. Primary risk to monitor: Potential: Clinical trial failures and regulatory setbacks.. This is not financial advice.
How frequently does CMVLF data refresh on this page?
CMVLF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CMVLF's recent stock price performance?
Recent price movement in Cellectis S.A. (CMVLF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary gene-editing technology. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.
- Clinical trial outcomes are inherently uncertain.